ALSO NOTED: New constipation data; GSK touts Cervarix study; Spherix transitions to biotech; and much more...
> Wyeth and Progenics say that a three-month extended study of their constipation therapy produced positive data. Release
> GlaxoSmithKline says that the biggest study yet has produced impressive data on the effectiveness of Cervarix in preventing cervical cancer. It will need plenty of powerful data if it intends to grab market share from Gardasil. Release
> Spherix is transitioning to a full-fledged biotech company with the $17 million sale of its subsidiary to Active Network. Report
> StemCells has agreed to a stay on its patent lawsuit with Neuralstem. Report
And Finally... With billions of dollars of revenue on the line, Amgen is asking Congress not to make "precipitate changes" in the way that the government reimburses for anemia drugs. Report
Be the first to comment
More stories about cervical cancer Gardasil GlaxoSmithKline Wyeth Amgen Anemia drugs competitors Cervarix
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets